Register a trial

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03598790




Registration number
NCT03598790
Ethics application status
Date submitted
16/07/2018
Date registered
26/07/2018

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Scientific title
A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Secondary ID [1] 0 0
2016-003427-30
Secondary ID [2] 0 0
PS0014
Universal Trial Number (UTN)
Trial acronym
BE BRIGHT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Plaque Psoriasis 0 0
Moderate to Severe Chronic Plaque Psoriasis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Bimekizumab

Experimental: Bimekizumab dose regimen 1 - Subjects are randomized to receive either dose regimen 1 (BKZ 1) or dose regimen 2 (BKZ 2) during the 144-week Treatment Period (open-label), those on BKZ 1 will switch to BKZ 2 at Week 24 or later (at the next scheduled clinic visit after Week 48)

Eligible subjects who completed the Treatment Period (open-label), and have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks.

Intervention Name: Bimekizumab

Experimental: Bimekizumab dose regimen 2 - Subjects are randomized to receive BKZ 2 during the 144-week Treatment Period (open-label).

Eligible subjects who completed the Treatment Period (open-label), would continue OLE2 on BKZ 2.

Intervention Name: Bimekizumab


Treatment: Drugs: Bimekizumab
Subjects will receive bimekizumab at pre-specified time-points.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP)
Assessment method [1] 0 0
The number of TEAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Timepoint [1] 0 0
From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Secondary outcome [1] 0 0
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to IMP
Assessment method [1] 0 0
The number of SAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk is used.
Timepoint [1] 0 0
From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Secondary outcome [2] 0 0
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to IMP
Assessment method [2] 0 0
The number of TEAEs leading to withdrawal adjusted by duration of exposure to study treatment were scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Timepoint [2] 0 0
From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Secondary outcome [3] 0 0
Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Non-responder Imputation)
Assessment method [3] 0 0
The PASI90 response assessments were based on improvement (reduction) of at least 90% in the PASI score compared to Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Timepoint [3] 0 0
Week 144 compared to Baseline of Feeder study for Cohort A and Baseline of PS0014 for Cohort B
Secondary outcome [4] 0 0
Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Observed Case)
Assessment method [4] 0 0
PASI90 response assessments were based on improvement (reduction) of at least 90% in the PASI score compared to Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum score is 0= no disease, maximum score is 72= maximal disease.
Timepoint [4] 0 0
Week 144 compared to Baseline of PS0014 for Cohort B
Secondary outcome [5] 0 0
Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Non-responder Imputation)
Assessment method [5] 0 0
The Investigator assessed the overall severity of psoriasis using the following 5-point scale: 0 = Clear (no signs of psoriasis; post-inflammatory hyperpigmentation may be present); 1= Almost clear (no thickening; normal to pink coloration; no to minimal focal scaling); 2= Mild (just detectable to mild thickening; pink to light red coloration; predominately fine scaling); 3= Moderate (clearly distinguishable to moderate thickening; dull to bright red coloration; moderate scaling); 4= Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). IGA response -IGA score of clear \[0\] or almost clear \[1\] with at least two category improvement from Baseline at visit timepoint.
Timepoint [5] 0 0
Week 144 compared to Baseline of Feeder study for Cohort A and Baseline of PS0014 for Cohort B
Secondary outcome [6] 0 0
Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Observed Case)
Assessment method [6] 0 0
The Investigator assessed the overall severity of psoriasis using the following 5-point scale: 0 = Clear (no signs of psoriasis; post-inflammatory hyperpigmentation may be present); 1= Almost clear (no thickening; normal to pink coloration; no to minimal focal scaling); 2= Mild (just detectable to mild thickening; pink to light red coloration; predominately fine scaling); 3= Moderate (clearly distinguishable to moderate thickening; dull to bright red coloration; moderate scaling); 4= Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). IGA response -IGA score of 0 or 1 at Week 144.
Timepoint [6] 0 0
Week 144 for Cohort B EP and GPP groups

Eligibility
Key inclusion criteria
Treatment Period (open-label)

* Subject is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, and medication intake according to the judgment of the Investigator
* Subject completes the feeder study (PS0008 [NCT03412747], PS0009 [NCT03370133], PS0013 [NCT03410992]) without meeting any withdrawal criteria
* Female subjects must be:

1. Postmenopausal: Menopause is defined as 12 consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause
2. Permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy)
3. Or, if of childbearing potential (and engaged in sexual activity that could result in procreation), must be willing to use a highly effective method of contraception throughout the duration of the study until 20 weeks after last administration of investigational medicinal product (IMP), and have a negative pregnancy test at the feeder study in final visit/Baseline visit in PS0014

OLE2 Period (USA and Canada)

* Completed the OLE Period without meeting any withdrawal criteria
* Compliant with ongoing clinical study requirements
* Female subject of childbearing potential must be willing to use highly effective method of contraception
* Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease (US only)
* Signed a separate OLE2 Period ICF
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Treatment Period (open-label)

* Subject has previously participated in this study
* Female subjects who plan to become pregnant during the study or within 20 weeks following last dose of study medication
* Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study. Note: For any subject with an ongoing Serious Adverse Event (SAE), or a history of serious infections in the feeder study, the Medical Monitor must be consulted prior to the subject's entry into PS0014, although the decision on whether to enroll the subject remains with the Investigator
* Subject has a positive or indeterminate interferon gamma release assay (IGRA) in a feeder study, unless appropriately evaluated and treated
* Subject may not participate in another study of a medicinal product or device under investigation other than the substudy
* Subject has a history of chronic alcohol or drug abuse within 6 months prior to Baseline as assessed by medical history, site interview, and/or results of the specified urine drug screen

OLE2 Period (USA and Canada)

* Subject has developed any medical or psychiatric condition, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in OLE2 Period
* Subject had a positive or indeterminate interferon-gamma release assay (IGRA) in the OLE study to Week 144, unless appropriately evaluated and treated
* Presence of active suicidal ideation or severe depression
* Subject has developed any active malignancy or history of malignancy prior to the OLE2 Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/09/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/11/2023
Sample size
Target
Accrual to date
Final
1353
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
PS0014 7 - Campbelltown
Recruitment hospital [2] 0 0
PS0014 3 - Carlton
Recruitment hospital [3] 0 0
PS0014 8 - East Melbourne
Recruitment hospital [4] 0 0
PS0014 4 - Fremantle
Recruitment hospital [5] 0 0
Ps0014 10 - Kogarah
Recruitment hospital [6] 0 0
PS0014 6 - Kogarah
Recruitment hospital [7] 0 0
PS0014 5 - Phillip
Recruitment hospital [8] 0 0
PS0014 2 - Westmead
Recruitment hospital [9] 0 0
PS0014 9 - Woolloongabba
Recruitment postcode(s) [1] 0 0
- Campbelltown
Recruitment postcode(s) [2] 0 0
- Carlton
Recruitment postcode(s) [3] 0 0
- East Melbourne
Recruitment postcode(s) [4] 0 0
- Fremantle
Recruitment postcode(s) [5] 0 0
- Kogarah
Recruitment postcode(s) [6] 0 0
- Phillip
Recruitment postcode(s) [7] 0 0
- Westmead
Recruitment postcode(s) [8] 0 0
- Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
New Hampshire
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Oklahoma
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Rhode Island
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Utah
Country [26] 0 0
Belgium
State/province [26] 0 0
Bruxelles
Country [27] 0 0
Belgium
State/province [27] 0 0
Charleroi
Country [28] 0 0
Belgium
State/province [28] 0 0
Liège
Country [29] 0 0
Canada
State/province [29] 0 0
Ajax
Country [30] 0 0
Canada
State/province [30] 0 0
Calgary
Country [31] 0 0
Canada
State/province [31] 0 0
Edmonton
Country [32] 0 0
Canada
State/province [32] 0 0
Halifax
Country [33] 0 0
Canada
State/province [33] 0 0
Hamilton
Country [34] 0 0
Canada
State/province [34] 0 0
Markham
Country [35] 0 0
Canada
State/province [35] 0 0
Mississauga
Country [36] 0 0
Canada
State/province [36] 0 0
Montreal
Country [37] 0 0
Canada
State/province [37] 0 0
North Bay
Country [38] 0 0
Canada
State/province [38] 0 0
Oakville
Country [39] 0 0
Canada
State/province [39] 0 0
Ottawa
Country [40] 0 0
Canada
State/province [40] 0 0
Peterborough
Country [41] 0 0
Canada
State/province [41] 0 0
Quebec City
Country [42] 0 0
Canada
State/province [42] 0 0
Richmond Hill
Country [43] 0 0
Canada
State/province [43] 0 0
Surrey
Country [44] 0 0
Canada
State/province [44] 0 0
Toronto
Country [45] 0 0
Canada
State/province [45] 0 0
Waterloo
Country [46] 0 0
Canada
State/province [46] 0 0
Windsor
Country [47] 0 0
Canada
State/province [47] 0 0
Winnipeg
Country [48] 0 0
Germany
State/province [48] 0 0
Berlin
Country [49] 0 0
Germany
State/province [49] 0 0
Bonn
Country [50] 0 0
Germany
State/province [50] 0 0
Darmstadt
Country [51] 0 0
Germany
State/province [51] 0 0
Dresden
Country [52] 0 0
Germany
State/province [52] 0 0
Erlangen
Country [53] 0 0
Germany
State/province [53] 0 0
Frankfurt
Country [54] 0 0
Germany
State/province [54] 0 0
Friedrichshafen
Country [55] 0 0
Germany
State/province [55] 0 0
Hamburg
Country [56] 0 0
Germany
State/province [56] 0 0
Heidelberg
Country [57] 0 0
Germany
State/province [57] 0 0
Lübeck
Country [58] 0 0
Germany
State/province [58] 0 0
Mahlow
Country [59] 0 0
Germany
State/province [59] 0 0
Münster
Country [60] 0 0
Germany
State/province [60] 0 0
Osnabrück
Country [61] 0 0
Germany
State/province [61] 0 0
Schweinfurt
Country [62] 0 0
Germany
State/province [62] 0 0
Schwerin
Country [63] 0 0
Germany
State/province [63] 0 0
Witten
Country [64] 0 0
Hungary
State/province [64] 0 0
Budapest
Country [65] 0 0
Hungary
State/province [65] 0 0
Debrecen
Country [66] 0 0
Hungary
State/province [66] 0 0
Encs
Country [67] 0 0
Hungary
State/province [67] 0 0
Gyula
Country [68] 0 0
Hungary
State/province [68] 0 0
Orosháza
Country [69] 0 0
Hungary
State/province [69] 0 0
Szeged
Country [70] 0 0
Hungary
State/province [70] 0 0
Szekszárd
Country [71] 0 0
Hungary
State/province [71] 0 0
Szolnok
Country [72] 0 0
Hungary
State/province [72] 0 0
Veszprém
Country [73] 0 0
Italy
State/province [73] 0 0
Roma
Country [74] 0 0
Japan
State/province [74] 0 0
Asahikawa
Country [75] 0 0
Japan
State/province [75] 0 0
Bunkyo-ku
Country [76] 0 0
Japan
State/province [76] 0 0
Chiyoda-ku
Country [77] 0 0
Japan
State/province [77] 0 0
Chuo-ku
Country [78] 0 0
Japan
State/province [78] 0 0
Fukuoka
Country [79] 0 0
Japan
State/province [79] 0 0
Gifu
Country [80] 0 0
Japan
State/province [80] 0 0
Hamamatsu
Country [81] 0 0
Japan
State/province [81] 0 0
Itabashi-ku
Country [82] 0 0
Japan
State/province [82] 0 0
Kobe
Country [83] 0 0
Japan
State/province [83] 0 0
Kurume
Country [84] 0 0
Japan
State/province [84] 0 0
Matsumoto
Country [85] 0 0
Japan
State/province [85] 0 0
Minato-ku
Country [86] 0 0
Japan
State/province [86] 0 0
Morioka
Country [87] 0 0
Japan
State/province [87] 0 0
Nagoya
Country [88] 0 0
Japan
State/province [88] 0 0
Nankoku
Country [89] 0 0
Japan
State/province [89] 0 0
Obihiro
Country [90] 0 0
Japan
State/province [90] 0 0
Osaka
Country [91] 0 0
Japan
State/province [91] 0 0
Sapporo
Country [92] 0 0
Japan
State/province [92] 0 0
Sendai
Country [93] 0 0
Japan
State/province [93] 0 0
Shimotsuke
Country [94] 0 0
Japan
State/province [94] 0 0
Shinagawa-ku
Country [95] 0 0
Japan
State/province [95] 0 0
Shinjuku-ku
Country [96] 0 0
Japan
State/province [96] 0 0
Takaoka
Country [97] 0 0
Japan
State/province [97] 0 0
Tokyo
Country [98] 0 0
Japan
State/province [98] 0 0
TSU
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Busan
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Gwangju
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Seongnam-si
Country [102] 0 0
Korea, Republic of
State/province [102] 0 0
Seoul
Country [103] 0 0
Poland
State/province [103] 0 0
Bialystok
Country [104] 0 0
Poland
State/province [104] 0 0
Bydgoszcz
Country [105] 0 0
Poland
State/province [105] 0 0
Gdansk
Country [106] 0 0
Poland
State/province [106] 0 0
Katowice
Country [107] 0 0
Poland
State/province [107] 0 0
Kielce
Country [108] 0 0
Poland
State/province [108] 0 0
Krakow
Country [109] 0 0
Poland
State/province [109] 0 0
Lodz
Country [110] 0 0
Poland
State/province [110] 0 0
Lublin
Country [111] 0 0
Poland
State/province [111] 0 0
Nowa Sol
Country [112] 0 0
Poland
State/province [112] 0 0
Poznan
Country [113] 0 0
Poland
State/province [113] 0 0
Szczecin
Country [114] 0 0
Poland
State/province [114] 0 0
Warszawa
Country [115] 0 0
Poland
State/province [115] 0 0
Wroclaw
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Moscow
Country [117] 0 0
Russian Federation
State/province [117] 0 0
Saint Petersburg
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Saratov
Country [119] 0 0
Russian Federation
State/province [119] 0 0
St. Petersburg
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Yaroslavl
Country [121] 0 0
Taiwan
State/province [121] 0 0
Taipei
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Dundee
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Liverpool
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Manchester
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Reading
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
UCB Biopharma SRL
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
UCB Cares
Address 0 0
001 844 599 2273
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

TypeOther DetailsAttachment
Study protocol
Statistical analysis plan



Results publications and other study-related documents



Results are available at https://clinicaltrials.gov/study/NCT03598790